Sabhir Madhi, MD

Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit
Johannesburg, Gauteng, South Africa

Disclosure(s): Pfizer, GSK, Medimmune, Merck & Co., Inc., Rahway, NJ, USA: Grant/Research Support, Honoraria

Presentation(s):

• 166 - A Phase 2b/3 Study to Evaluate the Efficacy and Safety of an Investigational Respiratory Syncytial Virus (RSV) Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants

  Thursday, October 17, 2024
  2:09 PM – 2:21 PM US PT